{'fraction_non_alphanumeric': 0.022727272727272728, 'fraction_numerical': 0.01048951048951049, 'mean_word_length': 5.586206896551724, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat

Background  Although cannabinoids have traditionally been used for the treatment and/or prevention of nausea and/or emesis, anorexia and weight loss induced by clinical use of antineoplastic drugs, their efficacy and safety in long‐term treatments are still controversial. Our aim was to analyze the effects of the non‐selective cannabinoid agonist WIN 55 212‐2 (WIN) on gastrointestinal (GI) dysmotility and other adverse effects induced by repeated cisplatin administration in the rat.